IL17A and proliferative diabetic retinopathy: Since this vascular impairment is a hallmark of non-proliferative diabetic retinopathy, these results suggest that anti-IL-17A could be a potentially novel therapeutic for early stage diabetic retinopathy in both Type I and II diabetics.